---
title: "Shanghai Henlius Biotech, Inc. (02696.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02696.HK.md"
symbol: "02696.HK"
name: "Shanghai Henlius Biotech, Inc."
industry: "Biotechnology"
---

# Shanghai Henlius Biotech, Inc. (02696.HK)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | HK Market |
| Website | [www.henlius.com](https://www.henlius.com) |

## Company Profile

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast an...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:10.000Z

**Overall: C (0.43)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 15 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.94% |  |
| Net Profit YoY | 19.24% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 10.25 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 38.31B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 6.29B |  |


**Multi Score**: C

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 27.54% | A |
| Profit Margin | 14.22% | B |
| Gross Margin | 78.00% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.94% | C |
| Net Profit YoY | 19.24% | B |
| Total Assets YoY | 17.89% | A |
| Net Assets YoY | 34.65% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 703.37% | B |
| OCF YoY | 2.94% | C |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.54 | C |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 70.49% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Henlius Biotech, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "27.54%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "14.22%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "78.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.94%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "19.24%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "17.89%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "34.65%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "703.37%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "2.94%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.54",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "70.49%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BEONE MEDICINES (HK.6160) | C | A | B | C | A | B |
| 02 | INNOVENT BIO (HK.1801) | B | A | C | B | A | B |
| 03 | 3SBIO (HK.1530) | A | B | C | A | C | B |
| 04 | BIOCYTOGEN-B (HK.2315) | A | A | C | D | B | B |
| 05 | HBM HOLDINGS-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 42.39 | 8/70 | 43.08 | 36.68 | 23.22 |
| PB | 10.25 | 43/70 | 10.68 | 9.03 | 6.32 |
| PS (TTM) | 6.03 | 16/70 | 6.15 | 5.22 | 3.33 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-10T16:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 9 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 70.50 |
| Highest Target | 130.96 |
| Lowest Target | 71.52 |

## References

- [Company Overview](https://longbridge.com/en/quote/02696.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02696.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02696.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.